GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Petlife Pharmaceuticals Inc (OTCPK:PTLF) » Definitions » 1-Year Share Buyback Ratio

PTLF (Petlife Pharmaceuticals) 1-Year Share Buyback Ratio : 0.00% (As of Feb. 2018 )


View and export this data going back to 2007. Start your Free Trial

What is Petlife Pharmaceuticals 1-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Petlife Pharmaceuticals's current 1-Year Share Buyback Ratio was 0.00%.

PTLF's 1-Year Share Buyback Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: -1.9
* Ranked among companies with meaningful 1-Year Share Buyback Ratio only.

Competitive Comparison of Petlife Pharmaceuticals's 1-Year Share Buyback Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Petlife Pharmaceuticals's 1-Year Share Buyback Ratio, along with its competitors' market caps and 1-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Petlife Pharmaceuticals's 1-Year Share Buyback Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Petlife Pharmaceuticals's 1-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Petlife Pharmaceuticals's 1-Year Share Buyback Ratio falls into.


;
;

Petlife Pharmaceuticals 1-Year Share Buyback Ratio Calculation

Petlife Pharmaceuticals's 1-Year Share Buyback Ratio for the quarter that ended in Feb. 2018 is calculated as

1-Year Share Buyback Ratio=(Shares Outstanding (EOP) (Feb. 2017 ) - Shares Outstanding (EOP) (Feb. 2018 )) / Shares Outstanding (EOP) (Feb. 2017 )
=(62.304 - 80.257) / 62.304
=-28.8%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Petlife Pharmaceuticals  (OTCPK:PTLF) 1-Year Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Petlife Pharmaceuticals 1-Year Share Buyback Ratio Related Terms

Petlife Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Petlife Pharmaceuticals Inc (OTCPK:PTLF) » Definitions » 1-Year Share Buyback Ratio
Comparable Companies
BOM:524590 BOM:524606 BOM:531521 BOM:539680 BOM:536565 PCYN BOM:532021 BOM:524516 BOM:540359 BOM:531015 TSXV:CIP.H BOM:531686 BOM:524314 BOM:511523 FRA:3SQ1 BOM:532167 BOM:524632 YBAO BKIT NBGV
Traded in Other Exchanges
N/A
Address
38 West Main Street, 6th Floor, Hancock, MD, USA, 21750
Website
http://www.petlifepharma.com
Petlife Pharmaceuticals Inc specializes in the research, development, sales, and support of advanced drugs and nutraceuticals for pet cancer and autoimmune related diseases such as arthritis. It develops potentiated veterinary cancer medications and nutraceuticals, under its tradename Vitalzul based on Escozine formula. The Vitalzul is a polarized, bioactive peptide extracted from the Blue Caribbean Scorpion (Rhopularus Princeps), which contains amino acids, proteins, and minerals.
Executives
Randy Steven White director, 10 percent owner, officer: President/Secretary/Treasurer OPLETALOVA 43, PRAGUE 2N 11000